Epigenomics' Q2 Revenues Tumble 57 Percent | GenomeWeb

NEW YORK (GenomeWeb News) – Epigenomics today reported that revenues in the second quarter fell 57 percent year over year.

The molecular diagnostics firm posted €156,000 ($192,992) in revenues during the three months ended June 30, down from €364,000 a year ago as it recognized no R&D revenues in the recently completed quarter while product sales and licensing income fell year over year.

Epigenomics' net loss for the quarter widened to €3.4 million from €3.0 million in Q2 2011.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.